CSIMarket
 


Biogen Inc   (BIIB)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

BIIB's Income from Cont. Operations Growth by Quarter and Year

Biogen Inc 's Income from Cont. Operations results by quarter and year




BIIB Income from Cont. Operations (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter December 357.50 1,439.70 944.90 -166.30
III Quarter September 703.90 1,545.90 1,442.90 1,226.10
II Quarter June 1,606.50 1,494.10 915.00 862.80
I Quarter March 1,392.60 1,408.80 1,171.20 747.50
FY   4,060.50 5,888.50 4,474.00 2,670.10



BIIB Income from Cont. Operations forth quarter 2020 Y/Y Growth Comment
Biogen Inc reported drop in Income from Cont. Operations in the forth quarter by -75.17% to $ 357.50 millions, from the same quarter in 2019.
The fall in the forth quarter Biogen Inc 's Income from Cont. Operations compares unfavorably to the Company's average Income from Cont. Operations increase of 13.21%.

Among companies who have reported forth quarter results in the Biotechnology & Drugs industry only one Company has achieved higher year on year Income from Cont. Operations results in the forth quarter. While Biogen Inc ' s Income from Cont. Operations meltdown of -75.17% ranks overall at the positon no. 160 in the forth quarter.




BIIB Income from Cont. Operations ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter December -75.17 % 52.37 % - -
III Quarter September -54.47 % 7.14 % 17.68 % 19.02 %
II Quarter June 7.52 % 63.29 % 6.05 % -17.7 %
I Quarter March -1.15 % 20.29 % 56.68 % -22.87 %
FY   -31.04 % 31.62 % 67.56 % -27.75 %

Financial Statements
Biogen Inc 's forth quarter 2020 Income from Cont. Operations $ 357.50 millions BIIB's Income Statement
Biogen Inc 's forth quarter 2019 Income from Cont. Operations $ 1,439.70 millions Quarterly BIIB's Income Statement
New: More BIIB's historic Income from Cont. Operations Growth >>


BIIB Income from Cont. Operations (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter December -49.21 % -6.87 % -34.51 % -
III Quarter September -56.18 % 3.47 % 57.69 % 42.11 %
II Quarter June 15.36 % 6.05 % -21.88 % 15.42 %
I Quarter March -3.27 % 49.1 % - 15.37 %
FY (Year on Year)   -31.04 % 31.62 % 67.56 % -27.75 %




Income from Cont. Operations forth quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #2
Healthcare Sector #12
Overall #160

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
413.15 % 13.21 % -86.75 %
(Sep. 30, 2006)   (June 30. 2006)
Income from Cont. Operations forth quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #2
Healthcare Sector #12
Overall #160
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
413.15 % 13.21 % -86.75 %
(Sep. 30, 2006)   (June 30. 2006)

Income from Cont. Operations by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Biogen Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
4345.95 % 78.55 % -56.18 %
(Sep. 30, 2004)  


BIIB's IV. Quarter Q/Q Income from Cont. Operations Comment
In the IV. Quarter 2020 Biogen Inc reported fall in Income from Cont. Operations sequentially by -49.21% to $ 357.50 millions, from $ 703.90 millions achived in the previous quarter.

It's not huge problem, as IV. Quarter Income from Cont. Operations always gravitate to plunge in the IV. Quarter.

Within Biotechnology & Drugs industry only one company achieved higher sequential Income from Cont. Operations growth. While Biogen Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is 157.


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #2
Healthcare Sector #12
Overall #157
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #2
Healthcare Sector #12
Overall #157
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
4345.95 % 78.55 % -56.18 %
(Sep. 30, 2004)  


BIIB's IV. Quarter Q/Q Income from Cont. Operations Comment
In the IV. Quarter 2020 Biogen Inc realized fall in Income from Cont. Operations from the third quarter by -49.21% to $ 357.50 millions, from $ 703.90 millions declared a quarter before.

It's not big issue, as IV. Quarter Income from Cont. Operations always gravitate to plunge in this quarter Ludvig Nilsson, a business veteran from Malmo wrote.

Within Biotechnology & Drugs industry only one company achieved higher sequential Income from Cont. Operations growth. While Biogen Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is 157.


Biogen Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
12 Months Ending
(Dec 31 2019)
Cumulative Income from Cont. Operations 12 Months Ending $ 4,060.50 $ 5,142.70 $ 5,984.70 $ 5,872.30 $ 5,888.50
Y / Y Income from Cont. Operations Growth (TTM) -31.04 % -4.65 % 13.12 % 24.63 % 31.62 %
Year on Year Income from Cont. Operations Growth Overall Ranking # 137 # 916 # 49 # 471 # 113
Seqeuential Income from Cont. Operations Change (TTM) -21.04 % -14.07 % 1.91 % -0.28 % 9.17 %
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # 160 # 1701 # 741 # 863 # 459




Cumulative Income from Cont. Operations growth Comment
Biogen Inc 's cumulative 12 months Income from Cont. Operations continue to drop, but on the faster rate at -31.04% year on year, at Dec 31 2020 compare to the -4.65% decrease at Sep 30 2020. If the Biogen Inc 's fiscal year would end at Dec 31 2020, annual Income from Cont. Operations would be $4,061 millions.

Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Income from Cont. Operations growth. While Total ranking has impoved so far to 137, from total ranking in previous quarter at 916.

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
413.15 %
13.21 %
-86.75 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 2
Healthcare Sector # 11
Overall # 137

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
1760.54 %
67.16 %
-78.16 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 12
S&P 500 # 160
Cumulative Income from Cont. Operations growth Comment
Biogen Inc 's cumulative 12 months Income from Cont. Operations continue to drop, but on the faster rate at -31.04% year on year, at Dec 31 2020 compare to the -4.65% decrease at Sep 30 2020. If the Biogen Inc 's fiscal year would end at Dec 31 2020, annual Income from Cont. Operations would be $4,061 millions.

Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Income from Cont. Operations growth. While Total ranking has impoved so far to 137, from total ranking in previous quarter at 916.

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
413.15 %
13.21 %
-86.75 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 2
Healthcare Sector # 11
Overall # 137

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
1760.54 %
67.16 %
-78.16 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 12
S&P 500 # 160




Other Income from Cont. Operations Growth
Biotechnology & Drugs Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
BIIB's Income from Cont. Operations Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for BIIB's Competitors
Income from Cont. Operations Growth for Biogen Inc 's Suppliers
Income from Cont. Operations Growth for BIIB's Customers

You may also want to know
BIIB's Annual Growth Rates BIIB's Profitability Ratios BIIB's Asset Turnover Ratio BIIB's Dividend Growth
BIIB's Roe BIIB's Valuation Ratios BIIB's Financial Strength Ratios BIIB's Dividend Payout Ratio
BIIB's Roa BIIB's Inventory Turnover Ratio BIIB's Growth Rates BIIB's Dividend Comparisons



Companies with similar Income from Cont. Operations drop for the quarter ending Dec 31 2020 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Dec 31 2020
Fresenius Medical Care Ag and Co Kgaa-0.19%$ -0.185 millions
Sensus Healthcare Inc -1.99%$ -1.991 millions
Xeris Pharmaceuticals Inc -2.78%$ -2.784 millions
Dr Reddys Laboratories Ltd-4.78%$ -4.779 millions
Amgen Inc -5.17%$ -5.167 millions
National Research Corporation-5.59%$ -5.587 millions
Fonar Corp-6.68%$ -6.676 millions
Zoetis Inc -6.77%$ -6.771 millions
Supernus Pharmaceuticals inc -7.13%$ -7.127 millions
Abiomed Inc -10.62%$ -10.617 millions
Lifevantage Corp-11.41%$ -11.411 millions
Icon Plc-11.41%$ -11.412 millions
Corcept Therapeutics Inc-11.53%$ -11.528 millions
Taro Pharmaceutical Industries Ltd-13.32%$ -13.318 millions
Radnet Inc -13.37%$ -13.369 millions
Davita Inc -15.43%$ -15.426 millions
Stryker Corp-21.66%$ -21.655 millions
Utah Medical Products Inc-21.71%$ -21.707 millions
Kamada Ltd-22.97%$ -22.970 millions
Teleflex Incorporated-28.93%$ -28.934 millions
Amarin Corp Plcuk-30.31%$ -30.306 millions
Novartis Ag-31.23%$ -31.235 millions
Pra Health Sciences inc -31.48%$ -31.476 millions
Springworks Therapeutics Inc -33.04%$ -33.036 millions
Pacific Health Care Organization Inc-35.40%$ -35.397 millions
Concert Pharmaceuticals Inc -37.70%$ -37.699 millions
Zynex Inc-39.36%$ -39.362 millions
Alexion Pharmaceuticals Inc -39.73%$ -39.730 millions
Gilead Sciences Inc -42.58%$ -42.581 millions
China Health Industries Holdings Inc -42.80%$ -42.797 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

LWAY's Profile

Stock Price

LWAY's Financials

Business Description

Fundamentals

Charts & Quotes

LWAY's News

Suppliers

LWAY's Competitors

Customers & Markets

Economic Indicators

LWAY's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071